News | News By Subject | News by Disease News By Date | Search News

Ovarian cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Clovis Oncology (CLVS) Stock Hammered After Revealing Mixed Results for Rucaparib     10/10/2016
Clovis Oncology (CLVS) Rockets as FDA Agrees to Priority Review of Rucaparib NDA     8/25/2016
Tesaro (TSRO)'s Phase III NOVA Trial of Niraparib Hits Primary Endpoint; NDA and MAA Planned for Q4 2016     6/29/2016
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S.     4/27/2016
Array BioPharma (ARRY) to Abandon Testing of Ovarian Cancer Drug     4/1/2016
1,000+ Women are Suing Johnson & Johnson (JNJ) for Allegedly Covering Up Baby Powder Cancer Risk for Decades     4/1/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015     3/24/2016
Maharashtra FDA to Test Johnson & Johnson (JNJ) Baby Powder for Cancer-Causing Substances After $75 Million U.S Verdict     3/10/2016
Merck KGaA (MKGAF.PK), Pfizer (PFE) Accelerate Immuno-Oncology Drug Avelumab into Phase III Ovarian and Bladder Cancer Trials     12/22/2015
Top 10 Best-Selling Biotech Drugs     10/2/2015
Celsion (CLSN) Updates Clinical Trial Data and Slashes 20% of Workforce     9/9/2015
ASCO15: Tiny Clovis Oncology (CLVS) Becomes an Even Bigger Takeover Target as Ovarian Cancer Drug Shrunk Tumors in 82% of Women     6/2/2015
ASCO15: BioSpace (DHX)'s Roundup of What You May Have Missed at ASCO So Far     6/1/2015
ASCO15: Analyst Calls ImmunoGen (IMGN)'s Phase I Ovarian Cancer Data "Impressive"     6/1/2015
Investors Wait With Bated Breath for ImmunoGen (IMGN)'s Ovarian Cancer Drug ASCO News     5/29/2015

News from Around the Web
AstraZeneca PLC (AZN) Is Now A Competitive Threat To Tesaro (TSRO) In Ovarian Cancer Maintenance Therapy     10/26/2016
The Race For PARP, A New Class Of Ovarian Cancer Drugs, Heats Up     10/10/2016
What's Behind FDA's Warning Against Ovarian Cancer Screening Tests?     9/13/2016
Parasite Found In Cat Poop May Actually Help Treat Ovarian Cancer, Dartmouth College Study     7/28/2016
Simplifying Access To Gene Testing For Women With Ovarian Cancer Improves Treatment Choices And Could Save Lives, Institute Of Cancer Research, Study     7/13/2016
Breast, Ovarian Cancer Risk May Have Association With Sense Of Smell, Keck Medicine of USC Study Reveals     10/22/2015
Tea And Citrus Products Could Lower Ovarian Cancer Risk, New University of East Anglia Research Finds     10/29/2014
No Link Found Between Fertility Drugs And Cancers, University of Illinois Study     7/1/2014
Ovarian Cancer Treatment Discovered By St. Joseph's Hospital Researchers     6/23/2014
Irregular Periods: Risk Factor For Ovarian Cancer? Public Health Institute Study     4/10/2014
A Cautionary Perspective on Angelina Jolie's Double Mastectomy     5/15/2013
Ovarian Cancer Vaccine Made From Tumors Yields Responses, University of Pennsylvania Study     4/9/2013
Night Shifts May be Linked to Increased Ovarian Cancer Risk, Fred Hutchinson Cancer Research Center Study     3/15/2013
New Type of Drug Leads to Hope Against Resistant Ovarian Cancer, University of Southern California Study     10/4/2012
Experimental Drug Inhibits Cell Signaling Pathway and Slows Ovarian Cancer Growth, University of California, Los Angeles (UCLA) Study     4/18/2011

Press Releases
Tesaro (TSRO) Announces Submission Of Niraparib New Drug Application For Platinum-Sensitive, Recurrent Ovarian Cancer     11/2/2016
AstraZeneca Canada (AZN) Release: Lynparza (Olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit For Women With Ovarian Cancer     11/1/2016
Propanc Files Application For Orphan Medicinal Product Designation In The EU For Ovarian Cancer     11/1/2016
Merrimack (MACK) Announces Acceptance For Review Of ANDA Filed By Actavis For Generic Doxorubicin Hydrochloride Liposome Injection (Aka DOXIL)     10/31/2016
AstraZeneca PLC (AZN) Breathes a Sigh of Relief as Lynparza Delays Ovarian Cancer Progression in Phase III Test     10/26/2016
Myriad Genetics (MYGN)’s BRACAnalysis CDx Test Identifies Patients With Ovarian Cancer Who Would Benefit From Second-Line Maintenance Treatment With Olaparib     10/26/2016
After Setback, Adaptimmune (ADAP) Revamps T Cell Study     10/14/2016
Adaptimmune (ADAP) Makes Move to Save Ovarian Cancer Study By Readjusting Its Trial Protocol     10/12/2016
Karolinska Development AB Portfolio Company Aprea Enrolls First Patients In Phase II Trial Of APR-246 In Ovarian Cancer     10/10/2016
Aprea Announces First Patients Enrolled In Phase II Clinical Study Of APR-246 For The Treatment Of High-Grade Serous Ovarian Cancer     10/10/2016
Myriad Genetics (MYGN)’s Mychoice HRD Test Identifies Patients With Ovarian Cancer Who May Benefit From Treatment With Niraparib     10/10/2016
AstraZeneca Canada (AZN) Release: Canada Denies Public Access To Potentially Life-Prolonging Ovarian Cancer Treatment LYNPARZA (Olaparib)     10/5/2016
Karyopharm (KPTI) Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication     9/28/2016
AstraZeneca PLC (AZN) Yanks Ovarian Cancer EU Application After 'Differences Of Opinion' With Regulators     9/22/2016
Novogen Limited (NVGN) Release: US FDA Approves Investigational New Drug (IND) Application For Cantrixil(TM) (TRX-E-002-1) In Ovarian Cancer     9/12/2016

//-->